Kathleen Engelman to HIV-1
This is a "connection" page, showing publications Kathleen Engelman has written about HIV-1.
Connection Strength
0.684
-
Engelman KD, Engelman AN. Long-Acting Cabotegravir for HIV/AIDS Prophylaxis. Biochemistry. 2021 06 08; 60(22):1731-1740.
Score: 0.483
-
Hahn PA, Shandilya S, da Costa LAB, da Silva LCF, O'Hagan D, Liang B, Engelman K, Gardner MR, Gao G, Fuchs SP, Martinez-Navio JM, Desrosiers RC, Ardeshir A, Magnani DM, Martins MA. The Immunogenicity of AAV-Encoded HIV-1 bNAbs in Rhesus Macaques Is Unaffected by a Short Course of the Immunomodulator CTLA4Ig. AIDS Res Hum Retroviruses. 2025 Dec; 41(12):567-579.
Score: 0.162
-
Dankwa S, Kosman C, Dennis M, Giorgi EE, Vuong K, Pahountis I, Garza A, Binuya C, McCarthy J, Mayer BT, Ngo JT, Enemuo CA, Carnathan DG, Stanfield-Oakley S, Berendam SJ, Weinbaum C, Engelman K, Magnani DM, Chan C, Ferrari G, Silvestri G, Amara RR, Chahroudi A, Permar SR, Fouda GG, Goswami R. A novel HIV triple broadly neutralizing antibody (bNAb) combination-based passive immunization of infant rhesus macaques achieves durable protective plasma neutralization levels and mediates anti-viral effector functions. PLoS One. 2024; 19(11):e0312411.
Score: 0.038